Jacobs Levy Equity Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Jacobs Levy Equity Management’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-652	Closed	-$280K	–	991
2021 Q3	$280K	Buy	+652	New	+$42.7K	﹤0.01%	944
2021 Q2	–	Sell	-1,416	Closed	-$553K	–	1049
2021 Q1	$553K	Buy	1,416 +668	+89%	+$50.2K	﹤0.01%	850
2020 Q4	$320K	Sell	748 -110	-13%	-$7.5K	﹤0.01%	912
2020 Q3	$730K	Sell	858 -216	-20%	-$24.7K	0.01%	718
2020 Q2	$889K	Buy	1,074 +333	+45%	+$27.8K	0.01%	695
2020 Q1	$275K	Sell	741 -874	-54%	-$62.3K	﹤0.01%	837
2019 Q4	$615K	Buy	1,615 +1,083	+204%	+$101K	0.01%	758
2019 Q3	$903K	Buy	532 +418	+367%	+$90.3K	0.01%	628
2019 Q2	$183K	Buy	+114	New	+$32.3K	﹤0.01%	883

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jacobs Levy Equity Management's KRSA Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2021, closing a stake of 652 shares — an estimated $280K sold.

Jacobs Levy Equity Management first reported a position in KRSA in Q2 2019 and held it in 9 quarters. The position peaked at $903K in Q3 2019. 51 funds tracked by Wall St. Rank hold KRSA as of Q4 2021.

Jacobs Levy Equity Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 652 Korsana Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $280K.
Jacobs Levy Equity Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 9 quarters.
Jacobs Levy Equity Management's Korsana Biosciences, Inc. Common Stock position peaked at $903K in Q3 2019.
51 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.